The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for rare diseases. Publishing research […]

Rail Vision (NASDAQ: RVSN) reported financial results for the second half and full year ended Dec. 31, 2025, citing revenue growth and continued operational progress as it expands its global footprint. The company advanced deployments with Israel Railways, secured follow-on orders in Latin America, expanded into Central America and launched a proof of concept in India, underscoring increasing adoption of […]

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance […]

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising. Securing reliable supplies of specialized rare earth elements is becoming increasingly important as demand rises across defense, energy and advanced manufacturing sectors. With this in mind, Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) recently announced that it is […]

Perpetuals.com (NASDAQ: PDC), a fintech company developing AI-powered trading products and prediction markets, announced that CEO Patrick Gruhn will deliver a presentation and participate in a live question-and-answer session with investors at the Emerging Growth Conference on April 1 at 12:35 p.m. Eastern Time. The free, online event will provide an overview of the company’s […]

Safe Pro Group (NASDAQ: SPAI) announced it has received a contract modification to provide continued support for its AI Edge Processing solution under an existing subcontract with the U.S. Government, reinforcing ongoing deployment of its AI-enabled defense and situational awareness technologies. The award supports the company’s efforts to advance real-time data processing and threat detection […]

Datavault AI (NASDAQ: DVLT) CEO Nate Bradley will present at a private investor roundtable on April 2, 2026, at The Mar-a-Lago Club in Palm Beach, Florida, marking his second invitation in two months amid growing institutional interest in the company’s data monetization, tokenization and AI-driven platform. The event builds on momentum from a February engagement […]

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, reported strong revenue growth and improving loan economics in its recently reported fourth-quarter 2025 results, highlighting a strategy that combines digital mortgage origination with new fee-based real-estate finance products. The fintech lender posted net revenue of $2.5 million in […]

Forward Industries (NASDAQ: FWDI), a Solana treasury company, recently finished its first full reporting period as the world’s largest Solana treasury. A recent article shares details from an announcement of the company’s fiscal first quarter 2026 operating and financial results, updates, milestones and future plans. “As of Dec. 31, 2025, Forward Industries has SOL holdings […]

U.S. Energy (NASDAQ: USEG) announced the pricing of an underwritten public offering of 8.8 million shares at $1.00 per share for gross proceeds of approximately $8.8 million, with closing expected March 10, 2026, subject to customary conditions. The company said it intends to use net proceeds to fund growth capital for its industrial gas development project, […]

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. The piece reads, “‘We upgrade HeartBeam to a BUY and High-Risk rating with […]

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]